Elutia Inc. (ELUT)

Market Cap	87.18M
Revenue (ttm)	24.38M
Net Income (ttm)	-53.95M
Shares Out	40.74M
EPS (ttm)	-1.86
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	24,498
Open	2.150
Previous Close	2.010
Day's Range	2.115 - 2.360
52-Week Range	1.870 - 5.240
Beta	0.96
Analysts	Strong Buy
Price Target	9.00 (+320.56%)
Earnings Date	May 8, 2025

About ELUT

Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation and breast reconstruction in the United States. It operates in three segments: Device Protection, Women’s Health, and Cardiovascular. The company offers EluPro, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators; and CanGaroo, which mitigates complications derived from implantable electronic devices and shortcomings of synthetic envelopes. It also provides Prox...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Oct 8, 2020
• Employees: 51
• Stock Exchange: NASDAQ
• Ticker Symbol: ELUT
• Website: https://elutia.com

Financial Performance

In 2024, Elutia's revenue was $24.38 million, a decrease of -1.50% compared to the previous year's $24.75 million. Losses were -$53.95 million, 43.3% more than in 2023.

Analyst Forecast

According to 2 analysts, the average rating for ELUT stock is "Strong Buy." The 12-month stock price forecast is $9.0, which is an increase of 320.56% from the latest price.

Price Target

$9.0

(320.56% upside)

Analyst Consensus: Strong Buy